
    
      All cases of ErbB2 positive metastatic breast cancer, receiving approved standard treatment
      with lapatinib-capecitabine, after trastuzumab-containing regimen progression in community
      setting can participate in this observational study, for a period of 12 months of observation
      since the start of the lapatinib-capecitabine treatment.
    
  